Better remission and response seen with bright light therapy before four weeks and after four weeks<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
FRIDAY, Oct. 4, 2024 (HealthDay News) — Bright light therapy (BLT) is an effective adjunctive treatment for nonseasonal depressive disorder, according to a review published online Oct. 2 in JAMA Psychiatry<\/em>.<\/p>\n Artur Menegaz de Almeida, from the Federal University of Mato Grosso in Sinop, Brazil, and colleagues conducted a systematic review and meta-analysis to examine the effectiveness of BLT as an adjunctive treatment for nonseasonal depressive disorders. Eleven unique trials were included, with data from 858 patients (75.6 percent females).<\/p>\n The researchers found that the BLT group had significantly better remission and response rates (remission: 40.7 versus 23.5 percent [odds ratio, 2.42]; response: 60.4 versus 38.6 percent [odds ratio, 2.34]). Subgroup analysis based on follow-up times also showed better remission and response with BLT (remission: less than four weeks, 27.4 versus 9.2 [odds ratio, 3.59]; more than four weeks, 46.6 versus 29.1 percent [odds ratio, 2.18]; response: less than four weeks, 55.6 versus 27.4 percent [odds ratio, 3.65]; more than four weeks, 63.0 versus 44.9 percent [odds ratio, 1.79]).<\/p>\n “Our study results suggest that BLT offers significant benefits as an adjunctive treatment for these conditions,” the authors write. “In addition, different follow-up times assessed in the subgroup analysis suggest that BLT not only increases remission and response rates but also accelerates the time to respond to initial treatment.”<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n